Elevance Health Inc. (ELV) Reports In-Line Q4 EPS, Beats on Revenue; Offers Guidance

Elevance Health Inc. (NYSE: ELV) reported Q4 EPS of $5.62, in-line with the analyst estimate of $5.62. Revenue for the quarter came in at $42.5 billion versus the consensus estimate of $42.22 billion.

Projected FY 2024 GAAP diluted EPS and adjusted diluted EPS2 of greater than $34.29 and $37.10 per share, respectively.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.

You May Also Be Interested In

• Elevance (ELV) PT Raised to $482 at Bernstein SocGen
• HSBC Upgrades Gilead Sciences (GILD) to Buy
• ​Trump said he was unaware of his earnings from crypto